Biggest IPO in years comes to Nasdaq, LTR Pharma to wow ASX with erectile dysfunction drug
A biotech tackling erectile dysfunction is set to join the ASX, as a healthcare IT company seeks $35 million. Meanwhile, a massive IPO looms in the US.
A biotech tackling erectile dysfunction is set to join the ASX, as a healthcare IT company seeks $35 million. Meanwhile, a massive IPO looms in the US.
Fashion juggernaut Shein is expected to go public in the US next year, with a massive valuation.
Founded in China in 2012 by little-known entrepreneur Chris Xu, Shein is an e-commerce fashion house headquartered in Singapore with revenue of $US23 billion in 2022.
For the latest investment news, sign up here for free Stockhead daily newsletters
The company is known for its $10 tops and $5 biker shorts, has a massive online advertising presence, and ships the majority of its products directly from China to more than a hundred countries.
JPMorgan Chase, Morgan Stanley and Goldman Sachs have reportedly been hired as underwriters for the IPO, and Bloomberg reports that a valuation of $US80-90 billion could be on the cards.
This would make Shein the largest initial public offering in years.
The stock will be hoping its entry will share similar success to that of German sandal maker Birkenstock (NYSE:BIRK).
Birk’s share price has risen by almost 20 per cent since its debut in October.
The stock has benefited from strong spending by US shoppers during the Thanksgiving holiday, as well as Black Friday and Cyber Monday.
But despite its grand entrance as a public company, Birkenstock shares are actually heavily shorted in the market. According to data from analytics firm Ortex, 5.71 million shares of Birkenstock (worth roughly $US260 million) are shorted.
The company is backed by French billionaire Bernard Arnault and his luxury goods empire Louis Vuitton Moet Hennessy (LVMH).
MORE FROM STOCKHEAD: Why ‘skin in the game’ is important | ASX stocks winners in ageless war on ageing| Meet a titan for women in resources
This month’s next arrivals
All dates are sourced from the ASX website. They could change without notice.
LTR PHARMA (ASX:LTP)
Expected listing: December 11
IPO: $7 million at $0.20
LTR Pharma is a clinical stage, biotech company pioneering a novel intranasal technology – SPONTAN – designed to treat erectile dysfunction in 10 minutes or less.
SPONTAN is said to provide on-demand delivery and faster effect. A lower dose provides less systematic exposure and reduced side effects.
According to LTP, benefits of SPONTAN include enhanced trans mucosal absorption, increased bioavailability and lower drug dose.
Erectile Dysfunction (ED) is a condition – which can be short-term or long-term – in which men are unable to get or keep an erection firm enough for satisfactory sexual intercourse.
LTP is targeting a US FDA New Drug Application (NDA) filing for SPONTAN, which is expected to be completed by the end of the first quarter of 2025 under the 505(b)(2) approval pathway regulatory strategy.
ENLITIC (ASX:ENL)
Expected listing: December 18
IPO: $35 million at $0.83
Enlitic is a healthcare IT company that harnesses AI to manage medical imaging data in radiology, such as MRI, CT, X-ray and ultrasound images.
The Enlitic platform standardises, protects, and analyses data to create a database that improves clinical workflows, increases efficiencies, and expands capacity.
The company says it owns the industry’s first localised real-world medical imaging database that unlocks the value of historical diagnostic images, aligned with real-time diagnostics, and linkage to real-world data across any critical care solutions.
Health care providers using the Enlitic platform would have their productivity increased, and have their costs decreased, says the company.
Visit Stockhead, where ASX small caps are big deals
FUSE MINERALS (ASX:FSE)
Expected listing: December 18
IPO: $10 million at $0.20
Fuse has three ongoing minerals exploration projects – Mt Sydney and Mt Sandman in WA, and Eastern Isaac in Queensland.
The flagship Mt Sydneyproject covers a strategic landholding (100 per cent-ownership) of 1119sq km, and is located on the under-explored Pilbara Craton-Paterson Province margin in WA.
Fuse’s work on the Mt Sydney project to date shows VHMS gossans high-grade polymetallic vein outcrops mineralised breccia, and magmatic copper-nickel drill targets across this very large area of tenure.
The project has limited past exploration, with only 1106m of drilling over 484sq km.
The Mt Sandman project is situated on the complex boundary of two major tectonic units of WA – the Proterozoic Gascoyne Province and the Palaeozoic Carnarvon Basin.
Rock chipping has confirmed base metal association with barite and carbonate rocks up to 6g/t Ag >1 per cent Pb & 0.3 per cent Zn.
The Eastern Isaac project in Queensland, meanwhile, is a 25 per cent ownership project, with an option to earn up to 80 per cent.
The project comprises three copper/gold project areas totalling 637sq km: Gotthardt of 93sq km, Valkyrie of 254sq km, and Hamilton Park of 290sq km.
Winners and sliders
There was only one listing over the past couple of weeks, Freedom Care Group (ASX:FCG). The shares have traded sideways since listing on November 30.
Freedom Care is a National Disability Insurance Scheme (NDIS) services provider headquartered in Western Sydney that provides a full suite of allied health and care services to individuals accepted into the NDIS, predominantly in the greater Sydney area.
The business is now looking to expand both organically and by acquiring other NDIS providers.
The company says an ASX listing will allow it to pursue additional growth opportunities, including geographic expansion to areas outside of New South Wales and by expanding its current offerings.
Meanwhile, the best ASX IPO this year has been that of James Bay Minerals (ASX:JBY).
The Canadian-based miner acquired a 100 per cent interest in one of the largest lithium exploration portfolios in the James Bay region, covering an area of 34,572ha or 346sq km.
James Bay has reported some positive news recently.
In early November, the company said it has strategically increased its La Grande Project area by 70 per cent to 30,168ha (302sq km) in James Bay, Canada.
The La Grande Project landholding has been strategically increased by 12,116ha (121sq km), while the Aqua Property, which directly adjoins and sits along trend from FIN Resources’ (ASX:FIN) recent outcropping spodumene discovery, has been increased by 5578ha (56sq km).
The company’s La Grande project is a highly prospective lithium property located along trend from Winsome Resources’ (ASX: WR1) Cancet Lithium Project, and Patriot Battery Metals’ (ASX:PMT) world-class CV5 deposit.
This week, the company reported that a significant number of new LCT pegmatite targets have been generated from airborne LiDAR at the Aqua Property.
Note: there was a 5:1 stock split for ACE
This content first appeared on stockhead.com.au
SUBSCRIBE
Get the latest Stockhead news delivered free to your inbox. Click here
Investor Guide: Health & Biotech FY2025
In this special investor guide, health and biotech guru Tim Boreham leads Stockhead’s deep dive into the most cutting edge sector on the ASX.
Investor Guide: Gold & Copper FY2025
Stockhead's writers - including mining guru Barry FitzGerald - take you inside the copper and gold markets, and zero in on juniors exploring for the next major mine.